ResearchMoz presents professional and in-depth study of "Pediatric Neuroblastoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025".
Pediatric neuroblastoma is a rare form of cancer which accounts for nearly 10% of all tumors in children. Pediatric neuroblastoma affects around 1,200 children in Europe and the U.S. each year. Neuroblastoma from primitive sympathetic ganglion cells found in the adrenal medulla or from other parts. Nearly 700 new cases of pediatric neuroblastoma are diagnosed in the U.S. each year, of these 90% patients are diagnosed before five years of age. According to the American Cancer Society, childhood cancer diagnosis rate is less than 1% of all types of cancers diagnosed each year.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1509416
The treatment and prognosis of individuals suffering from neuroblastoma depend on various biological and clinical factors such as age of the individual, disease stage, amplification of the MYCN oncogene, and histology. The risk levels of pediatric neuroblastoma are determined based on the above mentioned prognostic factors. The survival rate of individuals with low risk tumors is high. Individuals suffering with intermediate risk neuroblastoma have a survival rate of approximately 95%, following chemotherapy which varies in duration and intensity depending upon the risk factors associated prior to surgical resection. The average number of individuals with high risk of neuroblastoma is nearly 250 to 300 for each year. The treatment comprises intense chemotherapy, in certain cases autologous stem cell transplantation, and localized radiation. During the course, a six-month immunotherapy is also considered using dinutuximab and anti-GD2 antibody treatment in combination with GM-CSF and IL-2, administered in interchanging cycles and retinoic acid.
Increase in research activity in also expected to drive the global pediatric neuroblastoma treatment market during the forecast period. Launch of highly efficient and improved products, technological innovation, and rise in disease incidence and prevalence rate contribute to the growth of the global pediatric neuroblastoma treatment market during the forecast period. In 2015, United Therapeutics’ anti-GD2 antibody received approval from the EMA for the treatment of neuroblastoma in individuals aged between 12 months and 17 years. In the past few years, newer and more efficient therapies have been developed using advance technology. For example, in 2017, the European Commission granted marketing approval to Apeiron Biologic’s molecule APN311 to be used in rare pediatric neuroblastoma. The antibody is manufactured with CHO cells, which have a higher safety profile when compared to previous antibody based therapies. Government initiation to promote disease awareness and treatment is also expected to propel the global pediatric neuroblastoma market. Major restraints of the market are lack of approved treatment, high cost of treatment, and low levels of awareness in developing economies.
Make An Enquiry About TOC with tables & Figures @ https://www.researchmoz.us/enquiry.php?type=E&repid=1509416
Geographically, the global pediatric neuroblastoma treatment market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account for the largest share of the global market during the forecast period primarily due to higher awareness about the disease, better health care infrastructure for pediatric care, and presence of approved treatment for pediatric neuroblastoma. Europe is the second largest market for pediatric neuroblastoma treatment. The pediatric neuroblastoma market in Asia Pacific is expected to grow at a rapid pace during the forecast period due to rise in awareness, increase in research and development in the region, and improvement in health care infrastructure. The market in Latin America and Middle East & Africa is expected to grow at a moderate rate during the forecast period.
Only a few pharmaceutical manufacturers such as United Therapeutics Corp. and APEIRON Biologics AG have approved treatment for pediatric neuroblastoma.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis
The regional analysis covers:
North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Browse Report @ https://www.researchmoz.us/pediatric-neuroblastoma-treatment-market-global-industry-analysis-size-share-growth-trends-and-forecast-2017-2025-report.html
Highlights of the report:
A complete backdrop analysis, which includes an assessment of the parent market
Important changes in market dynamics
Market segmentation up to the second or third level
Historical, current, and projected size of the market from the standpoint of both value and volume
Reporting and evaluation of recent industry developments
Market shares and strategies of key players
Emerging niche segments and regional markets
An objective assessment of the trajectory of the market
Recommendations to companies for strengthening their foothold in the market
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
Pediatric neuroblastoma is a rare form of cancer which accounts for nearly 10% of all tumors in children. Pediatric neuroblastoma affects around 1,200 children in Europe and the U.S. each year. Neuroblastoma from primitive sympathetic ganglion cells found in the adrenal medulla or from other parts. Nearly 700 new cases of pediatric neuroblastoma are diagnosed in the U.S. each year, of these 90% patients are diagnosed before five years of age. According to the American Cancer Society, childhood cancer diagnosis rate is less than 1% of all types of cancers diagnosed each year.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1509416
The treatment and prognosis of individuals suffering from neuroblastoma depend on various biological and clinical factors such as age of the individual, disease stage, amplification of the MYCN oncogene, and histology. The risk levels of pediatric neuroblastoma are determined based on the above mentioned prognostic factors. The survival rate of individuals with low risk tumors is high. Individuals suffering with intermediate risk neuroblastoma have a survival rate of approximately 95%, following chemotherapy which varies in duration and intensity depending upon the risk factors associated prior to surgical resection. The average number of individuals with high risk of neuroblastoma is nearly 250 to 300 for each year. The treatment comprises intense chemotherapy, in certain cases autologous stem cell transplantation, and localized radiation. During the course, a six-month immunotherapy is also considered using dinutuximab and anti-GD2 antibody treatment in combination with GM-CSF and IL-2, administered in interchanging cycles and retinoic acid.
Increase in research activity in also expected to drive the global pediatric neuroblastoma treatment market during the forecast period. Launch of highly efficient and improved products, technological innovation, and rise in disease incidence and prevalence rate contribute to the growth of the global pediatric neuroblastoma treatment market during the forecast period. In 2015, United Therapeutics’ anti-GD2 antibody received approval from the EMA for the treatment of neuroblastoma in individuals aged between 12 months and 17 years. In the past few years, newer and more efficient therapies have been developed using advance technology. For example, in 2017, the European Commission granted marketing approval to Apeiron Biologic’s molecule APN311 to be used in rare pediatric neuroblastoma. The antibody is manufactured with CHO cells, which have a higher safety profile when compared to previous antibody based therapies. Government initiation to promote disease awareness and treatment is also expected to propel the global pediatric neuroblastoma market. Major restraints of the market are lack of approved treatment, high cost of treatment, and low levels of awareness in developing economies.
Make An Enquiry About TOC with tables & Figures @ https://www.researchmoz.us/enquiry.php?type=E&repid=1509416
Geographically, the global pediatric neuroblastoma treatment market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account for the largest share of the global market during the forecast period primarily due to higher awareness about the disease, better health care infrastructure for pediatric care, and presence of approved treatment for pediatric neuroblastoma. Europe is the second largest market for pediatric neuroblastoma treatment. The pediatric neuroblastoma market in Asia Pacific is expected to grow at a rapid pace during the forecast period due to rise in awareness, increase in research and development in the region, and improvement in health care infrastructure. The market in Latin America and Middle East & Africa is expected to grow at a moderate rate during the forecast period.
Only a few pharmaceutical manufacturers such as United Therapeutics Corp. and APEIRON Biologics AG have approved treatment for pediatric neuroblastoma.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis
The regional analysis covers:
North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Browse Report @ https://www.researchmoz.us/pediatric-neuroblastoma-treatment-market-global-industry-analysis-size-share-growth-trends-and-forecast-2017-2025-report.html
Highlights of the report:
A complete backdrop analysis, which includes an assessment of the parent market
Important changes in market dynamics
Market segmentation up to the second or third level
Historical, current, and projected size of the market from the standpoint of both value and volume
Reporting and evaluation of recent industry developments
Market shares and strategies of key players
Emerging niche segments and regional markets
An objective assessment of the trajectory of the market
Recommendations to companies for strengthening their foothold in the market
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
No comments:
Post a Comment